Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of Orexigen Therapeutics, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of purchasers of the common stock of Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) (NASDAQ:OREX) concerning possible violations of federal securities laws between July 20, 2009, and April 12, 2010.

Orexigen is a biopharmaceutical company, focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s lead combination product candidates include Contrave, which is a combination of two established drugs, bupropion and naltrexone, in a sustained-release formulation for the treatment of obesity. The investigation focuses on allegations that certain statements made by the Company during this period about the effectiveness of Contrave were materially false and/or misleading.

If you purchased Orexigen between July 20, 2009, and April 12, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.



CONTACT:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Legal

MEDIA:

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.